Application of RNA-targeting Cas9 to Fuchs' dystrophy
$322,405R01FY2021EYNIH
University Of California, San Diego, La Jolla CA
Investigators
Linked publications & trials
Paper 36510111Paper 35767654Paper 35697782Paper 35236841Paper 33172304Paper 33147453Paper 33077937Paper 32015437Paper 31317428Paper 30998900Paper 30710013Paper 30068547
Abstract
PROJECT SUMMARY Fuchs? endothelial corneal dystrophy is a degenerative disorder of the eye?s corneal endothelium and the most common indication for corneal transplantation. The majority of patients carry a trinucleotide repeat expansion in the TCF4 gene, causing sequestration of the MBNL1 splicing factor and widespread mis-splicing of MBNL1- regulated transcripts. Here we propose to use patient-derived cells to provide a characterization of the molecular pathology of this disease and evaluate the potential of our newly developed RNA-targeting CRISPR/Cas9 system as a therapeutic modality to eliminate toxic repeat expansions in TCF4 RNA transcripts.
View original record on NIH RePORTER →